TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice TargetHot
TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.
TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.